The biology of VEGF and its receptors
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Ferrara et al., 2003
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“VEGF induces a potent angiogenic response in a variety of in vivo model”
BackgroundSelf-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“VEGF is known also as vascular permeability factor, based on its ability to induce vascular leakag”
BackgroundFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Many molecules have been implicated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF, or scatter factor), tumor necrosis factor-α, angiogenin, interleukin (IL)-8 and the angiopoietin”
Background
Research works printed but not linked: 3
- Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
- Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Cited by
Items 101–200 of 1,056
VEGF as a Therapeutic Target in Cancer
Ferrara, N. (2005) · Oncology · doi:10.1159/000088479 · Cited by 578
Self-citationTumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
“Vascular endothelial growth factor (VEGF) is a strong mitogen and survival factor of vascular endothelial cells, one of the most potent angiogenic factors and the target of the first FDA approved antiangiogenic agent, Avastin [Ferrara et al., 2003].”
BackgroundVascular Endothelial Growth Factor as a Target for Anticancer Therapy
Ferrara, N. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-2 · Cited by 574
“TGF-β, which leads to upregulation of VEGF, has, nonetheless, been found to downregulate VEGFR mRNA levels in endothelial cells, while TNF-α has been variously reported to have positive and negative effects on expression of VEGFR-2 [ 3 ].”
BackgroundInfluentialSelf-citationMolecular pathology of age-related macular degeneration
Ding, X., Patel, M., & Chan, C.-C. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.10.001 · Cited by 582
“VEGF It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
BackgroundButler, J. M., Kobayashi, H., & Rafii, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2791 · Cited by 578
Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective
Kowanetz, M., & Ferrara, N. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1520 · Cited by 564
Self-citationHCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 550
“GBM are also one of the most vascularized and edematous tumors as they express high levels of VEGF (Ferrara et al., 2003; Sundberg et al., 2001; van Bruggen et al., 1999).”
Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis
Sawamiphak, S., Seidel, S., Essmann, C. L., Wilkinson, G. A., Pitulescu, M. E., Acker, T., & Acker-Palmer, A. (2010) · Nature · doi:10.1038/nature08995 · Cited by 534
Tang, N., Wang, L., Esko, J., Giordano, F. J., Huang, Y., Gerber, H.-P., Ferrara, N., & Johnson, R. S. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.026 · Cited by 540
Self-citationBiology of vascular endothelial growth factors
Roy, H., Bhardwaj, S., & Ylä-Herttuala, S. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.087 · Cited by 537
“suggested that the VEGF165 is probably the major isoform that brings about the VEGF-A actions [1,15].”
BackgroundInfluentialGarcia, A. A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D. D., Roman, L., Groshen, S., Swenson, S., Markland, F., Gandara, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1939 · Cited by 547
A mechanosensitive transcriptional mechanism that controls angiogenesis
Mammoto, A., Connor, K. M., Mammoto, T., Yung, C. W., Huh, D., Aderman, C. M., Mostoslavsky, G., Smith, L. E. H., & Ingber, D. E. (2009) · Nature · doi:10.1038/nature07765 · Cited by 527
From angiogenesis to neuropathology
Greenberg, D. A., & Jin, K. (2005) · Nature · doi:10.1038/nature04481 · Cited by 532
“The tyrosine kinase receptors and downstream protein kinases implicated in VEGF signalling in the CNS have been essentially identical to those described previously in non-neural tissues, and include VEGFR-2 and to some extent VEGFR-1 receptors, as well as mitogen-activated protein kinases (MAPKs), phosphatidylinositol…”
BackgroundThe potential impact of the preparation rich in growth factors (PRGF) in different medical fields
Anitua, E., Sánchez, M., Orive, G., & Andía, I. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.06.037 · Cited by 526
“For example, platelet-derived growth factor (PDGF) is a powerful mitogen for connective tissue cells [10], transforming growth factor-b (TGF-b) stimulates osteoprogenitor cells to proliferate but also blocks in later stages cell differentiation and mineralization [11], insulinlike growth factor (IGF-I) might promote t…”
BackgroundVan Cutsem, E., Rivera, F., Berry, S., Kretzschmar, A., Michael, M., DiBartolomeo, M., Mazier, M.-A., Canon, J.-L., Georgoulias, V., Peeters, M., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp233 · Cited by 532
Biology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
“…growth factor-α (TGFα), TGFβ, keratinocyte growth factor, insulin-like growth factor 1, fibroblast growth factor (FGF) and PDGF, upregulate VEGFA mRNA expression, suggesting that release of such factors cooperates with local hypoxia in regulating VEGF release in the microenvironment 24 .”
BackgroundSelf-citationSystemic Treatment of Colorectal Cancer
Wolpin, B. M., & Mayer, R. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.098 · Cited by 504
Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy
Choi, S., & Myers, J. N. (2008) · Journal of Dental Research · doi:10.1177/154405910808700104 · Cited by 516
“VEGF plays a pivotal role in the regulation of normal and pathological angiogenesis, and it also increases vessel permeability and enhances endothelial cell growth, proliferation, migration, and differentiation (Ferrara et al., 2003).”
BackgroundEndothelium structure and function in kidney health and disease
Jourde-Chiche, N., Fakhouri, F., Dou, L., Bellien, J., Burtey, S., Frimat, M., Jarrot, P.-A., Kaplanski, G., Le Quintrec, M., Pernin, V., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0098-z · Cited by 493
Tian, S., Quan, H., Xie, C., Guo, H., Lü, F., Xu, Y., Li, J., & Lou, L. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01939.x · Cited by 513
Inorganic nanomaterials with rapid clearance for biomedical applications
Wang, X., Zhong, X., Li, J., Liu, Z., & Cheng, L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00461h · Cited by 509
Angiogenesis and chronic inflammation: cause or consequence?
Costa, C., Incio, J., & Soares, R. (2007) · Angiogenesis · doi:10.1007/s10456-007-9074-0 · Cited by 504
“signaling on ECs represents the major rate-limiting step during the process [32].”
BackgroundGirardi, G., Yarilin, D., Thurman, J. M., Holers, V. M., & Salmon, J. E. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061022 · Cited by 508
Storkebaum, E., Lambrechts, D., Dewerchin, M., Moreno-Murciano, M.-P., Appelmans, S., Oh, H., Van Damme, P., Rutten, B., Man, W. Y., De Mol, M., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1360 · Cited by 494
“We previously reported that low levels of the angiogenic factor VEG”
BackgroundFluid forces control endothelial sprouting
Song, J. W., & Munn, L. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105316108 · Cited by 498
“We speculate that, whereas VEGF guides sprouts toward hypoxic regions (1, 5, 9), interstitial flow directs them to other vessels, against the direction of interstitial flow, and consequently, toward vessels that have higher microvascular pressure than their own.”
BackgroundBringing new life to damaged bone: The importance of angiogenesis in bone repair and regeneration
Stegen, S., van Gastel, N., & Carmeliet, G. (2015) · Bone · doi:10.1016/j.bone.2014.09.017 · Cited by 477
“The timely formation of new blood vessels is a critical process during embryonic and fetal development [7,8].”
BackgroundWeis, S., Cui, J., Barnes, L., & Cheresh, D. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200408130 · Cited by 477
“Although VEGF signaling occurs through binding to its three cell surface receptors VEGFR-1 (Flt), VEGFR-2 (Flk/ KDR), and/or neuropilin1/2, the permeability-inducing effects of VEGF have been attributed to signaling downstream of Flk exclusively (Ferrara et al., 2003).”
BackgroundCancer drugs and the heart: importance and management
Suter, T. M., & Ewer, M. S. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs181 · Cited by 472
“Angiogenesis inhibitors (anti-vascular endothelial growth factor) cancer drugs Angiogenesis inhibitors that target VEGF with either antibodies against VEGF (bevacizumab) or small molecule TKIs (sunitinib, sorafenib) prolong the lives of patients with a variety of solid tumours, including metastatic colorectal, renal c…”
BackgroundShojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902280106 · Cited by 471
“Mice were killed when tumors reached 2,000 mm (3).”
BackgroundSelf-citationAngiogenesis Inhibitors: Current Strategies and Future Prospects
Cook, K. M., & Figg, W. D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20075 · Cited by 474
VEGF-A and the Induction of Pathological Angiogenesis
Nagy, J. A., Dvorak, A. M., & Dvorak, H. F. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.134925 · Cited by 474
Biosensor technology: recent advances in threat agent detection and medicine
Kirsch, J., Siltanen, C., Zhou, Q., Revzin, A., & Simonian, A. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60141b · Cited by 462
Intensive insulin therapy protects the endothelium of critically ill patients
Langouche, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25385 · Cited by 467
eIF4E – from translation to transformation
Mamane, Y., Petroulakis, E., Rong, L., Yoshida, K., Ler, L. W., & Sonenberg, N. (2004) · Oncogene · doi:10.1038/sj.onc.1207549 · Cited by 449
Structural and functional characteristics of S1P receptors
Sanchez, T., & Hla, T. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20127 · Cited by 456
“SinceVEGF is involved in many different pathological conditions, like tumor-induced angiogenesis, intraocular neovascular syndromes, or inflammatory disorders (reviewed in [Ferrara et al., 2003]), among others, S1P receptor ligandsmay antagonize the effects of VEGF in these situations, by promoting the formation of we…”
BackgroundCancer-associated adipocytes: key players in breast cancer progression
Wu, Q., Li, B., Li, Z., Li, J., Sun, S., & Sun, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0778-6 · Cited by 462
Molecular Mediators of Angiogenesis
Ucuzian, A. A., Gassman, A. A., East, A. T., & Greisler, H. P. (2010) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e3181c7ed82 · Cited by 446
“The soluble or membrane-bound form binds most commonly to two transmembrane receptor tyrosine kinases, VEGFR-1 (Flt-1) and VEGFR-2 (kinase insert domain receptor [KDR]/Flk-1).(34,35) A third transmembrane receptor neuropilin- 1, which binds the VEGF-A splice variant of VEGF165, is involved in capillary morphogenesis a…”
BackgroundWang, H.-W., Trotter, M. W. B., Lagos, D., Bourboulia, D., Henderson, S., Mäkinen, T., Elliman, S., Flanagan, A. M., Alitalo, K., & Boshoff, C. (2004) · Nature Genetics · doi:10.1038/ng1384 · Cited by 460
“We tested all plasma samples for vascular endothelial growth factor (VEGF) and for the lymphangiogenic molecule VEGF-”
MethodRole of Angiogenesis in Cardiovascular Disease: A Critical Appraisal
Khurana, R., Simons, M., Martin, J. F., & Zachary, I. C. (2005) · Circulation · doi:10.1161/circulationaha.105.535294 · Cited by 451
Gene Expression in the Urinary Bladder
Dyrskjøt, L., Kruhøffer, M., Thykjaer, T., Marcussen, N., Jensen, J. L., Møller, K., & Ørntoft, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3620 · Cited by 451
“We found the GG2-1 gene, which may encode an antiapoptotic protein (inferred from structural domains), and the VEGF gene, which encodes a protein that is a prognostic marker for stage progression and recurrence in bladder cancer (30, 31) and is involved in angiogenesis (32).”
BackgroundCo3O4 Nanoparticles with Multi-Enzyme Activities and Their Application in Immunohistochemical Assay
Dong, J., Song, L., Yin, J.-J., He, W., Wu, Y., Gu, N., & Zhang, Y. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am405009f · Cited by 454
FDA-approved bone grafts and bone graft substitute devices in bone regeneration
Gillman, C. E., & Jayasuriya, A. C. (2021) · Materials Science and Engineering: C · doi:10.1016/j.msec.2021.112466 · Cited by 417
Current progress of siRNA/shRNA therapeutics in clinical trials
Burnett, J. C., Rossi, J. J., & Tiemann, K. (2011) · Biotechnology Journal · doi:10.1002/biot.201100054 · Cited by 444
“VEGF is the predominant mediator of angiogenesis and is increased in neovascular membranes of AMD patients [57, 58] and in DME patients [59].”
BackgroundBrissova, M., Shostak, A., Shiota, M., Wiebe, P. O., Poffenberger, G., Kantz, J., Chen, Z., Carr, C., Jerome, W. G., Chen, J., et al. (2006) · Diabetes · doi:10.2337/db06-0690 · Cited by 442
“It is upregulated in hypoxic tissues and in tumors that have outgrown their blood supply (10).”
BackgroundLee, C., Kim, M.-J., Kumar, A., Lee, H.-W., Yang, Y., & Kim, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02249-0 · Cited by 365
Silk fibroin nanoparticle as a novel drug delivery system
Mottaghitalab, F., Farokhi, M., Shokrgozar, M. A., Atyabi, F., & Hosseinkhani, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.020 · Cited by 444
Keloids: The paradigm of skin fibrosis — Pathomechanisms and treatment
Andrews, J. P., Marttala, J., Macarak, E., Rosenbloom, J., & Uitto, J. (2016) · Matrix Biology · doi:10.1016/j.matbio.2016.01.013 · Cited by 433
Cardiovascular Effects of Exercise Training: Molecular Mechanisms
Gielen, S., Schuler, G., & Adams, V. (2010) · Circulation · doi:10.1161/circulationaha.110.939959 · Cited by 433
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
Tabernero, J. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0404 · Cited by 437
“Under normal oxygen tension, HIF expression is downregulated via proteosomal degradation (9, 24).”
BackgroundInfluentialCai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Dickson, P. V., Hamner, J. B., Sims, T. L., Fraga, C. H., Ng, C. Y. C., Rajasekeran, S., Hagedorn, N. L., McCarville, M. B., Stewart, C. F., & Davidoff, A. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0278 · Cited by 441
“Vascular endothelial growth factor (VEGF) is well established as a central mediator in this process (2, 3).”
BackgroundNishimura, S., Manabe, I., Nagasaki, M., Hosoya, Y., Yamashita, H., Fujita, H., Ohsugi, M., Tobe, K., Kadowaki, T., Nagai, R., et al. (2007) · Diabetes · doi:10.2337/db06-1749 · Cited by 440
“The fact that VEGF receptor-1 is required for the recruitment of hematopoietic precursors and the migration of monocytes and macrophages (37,38) supports this model.”
VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants
Warner-Schmidt, J. L., & Duman, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610282104 · Cited by 438
Ahn, G.-O., & Brown, J. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.11.032 · Cited by 432
“, 2000), a growth factor that is critical for survival and growth of endothelial cells (Ferrara et al., 2003).”
BackgroundTreatment-Related Mortality With Bevacizumab in Cancer Patients: A Meta-analysis
Ranpura, V., Hapani, S., & Wu, S. (2011) · JAMA · doi:10.1001/jama.2011.51 · Cited by 428
Evans, C. J., Hartenstein, V., & Banerjee, U. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00335-6 · Cited by 433
Intussusceptive angiogenesis: Its emergence, its characteristics, and its significance
Burri, P. H., Hlushchuk, R., & Djonov, V. (2004) · Developmental Dynamics · doi:10.1002/dvdy.20184 · Cited by 413
“We know that a multitude of cellular reactions and molecules are involved in the establishment of a functional vascular tree (Carmeliet, 2000, 2003; Conway et al., 2001; Ferrara et al., 2003; Jain, 2003).”
BackgroundDeryugina, E. I., & Quigley, J. P. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.04.004 · Cited by 422
“However, the VEGF-A (VEGF) molecule represents a critical factor that regulates practically all aspects of tumor-induced angiogenesis, including endothelial cell sprouting and assembly, lumen formation, vessel dilation and permeability, and the microarchitecture and patterning of vascular networks (Chung and Ferrara,…”
BackgroundSHED Differentiate into Functional Odontoblasts and Endothelium
Sakai, V. T., Zhang, Z., Dong, Z., Neiva, K. G., Machado, M. A. A. M., Shi, S., Santos, C. F., & Nör, J. E. (2010) · Journal of Dental Research · doi:10.1177/0022034510368647 · Cited by 423
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
Wang, Y., Fei, D., Vanderlaan, M., & Song, A. (2004) · Angiogenesis · doi:10.1007/s10456-004-8272-2 · Cited by 430
“It is generally accepted that VEGF recognizes and transmit signals mainly through two receptors: VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1), which are both expressed on EC surface [12].”
BackgroundResistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 396
“It was noted in most solid tumors and some hematologic malignancies (20).”
BackgroundMolecular Link Mechanisms between Inflammation and Cancer
B. Vendramini-Costa, D., & E. Carvalho, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802083707 · Cited by 417
The discovery of placenta growth factor and its biological activity
De Falco, S. (2012) · Experimental and Molecular Medicine · doi:10.3858/emm.2012.44.1.025 · Cited by 425
“Like the others members of VEGF family (Ferrara et al., 2003; Takahashi and Shibuya, 2005), different isoforms due to alternative splicing are encoded by human plgf gene.”
BackgroundThe theory of facilitated variation
Gerhart, J., & Kirschner, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701035104 · Cited by 409
Hamerlik, P., Lathia, J. D., Rasmussen, R., Wu, Q., Bartkova, J., Lee, M., Moudry, P., Bartek, J., Fischer, W., Lukas, J., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111424 · Cited by 406
“Autocrine VEGF-VEGFR2 signaling is enhanced by interaction with NRP1 and remains active in the endosomal compartment of GBM cells Next, we asked whether Neuropilin-1 (NRP1), a nonsignaling co-receptor of VEGFR2 in endothelial cells (Ferrara et al., 2003), could be present in the GBM cells and possibly interact with VE…”
BackgroundHeparin Binding Nanostructures to Promote Growth of Blood Vessels
Rajangam, K., Behanna, H. A., Hui, M. J., Han, X., Hulvat, J. F., Lomasney, J. W., & Stupp, S. I. (2006) · Nano Letters · doi:10.1021/nl0613555 · Cited by 412
VEGF: an Essential Mediator of Both Angiogenesis and Endochondral Ossification
Dai, J., & Rabie, A. B. M. (2007) · Journal of Dental Research · doi:10.1177/154405910708601006 · Cited by 404
“The main receptors involved in VEGF signal transduction are the PDGF receptor subfamily of receptor tyrosine kinases (RTKs)—namely, VEGFR-1, VEGFR-2, VEGFR-3—as well as co-receptors, such as NRP-1 and -2 and HSPGs (Ferrara et al., 2003) (Fig.”
InfluentialNeuropilins: structure, function and role in disease
Pellet-Many, C., Frankel, P., Jia, H., & Zachary, I. (2008) · Biochemical Journal · doi:10.1042/bj20071639 · Cited by 395
Angiogenesis: Where Do We Stand Now?
Simons, M. (2005) · Circulation · doi:10.1161/01.cir.0000159345.00591.8f · Cited by 411
Rini, B. I., & Small, E. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.186 · Cited by 408
The hypoxic response of tumors is dependent on their microenvironment
Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.-P., Johnson, R. S., & Bergers, G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00194-6 · Cited by 408
“…HIFwt astrocytomas appeared less distorted, and showed signs angiogenic candidate, because its transcription is partly induced by the HIF-1 complex (Ferrara et al., 2003; Pugh and Ratcliffe, of decreased branching, in comparison to the intracranial HIFwt astrocytomas (Figures 7A and 7C).”
BackgroundSelf-citationUnderstanding the biology of angiogenesis: Review of the most important molecular mechanisms
Otrock, Z. K., Mahfouz, R. A. R., Makarem, J. A., & Shamseddine, A. I. (2007) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2007.04.001 · Cited by 386
VEGFA is necessary for chondrocyte survival during bone development
Zelzer, E., Mamluk, R., Ferrara, N., Johnson, R. S., Schipani, E., & Olsen, B. R. (2004) · Development · doi:10.1242/dev.01053 · Cited by 401
“Although VEGFA is best known for its activity as an angiogenic factor (Ferrara et al., 2003), it has been shown to be a survival factor for endothelial and hematopoietic stem cells (Benjamin et al., 1999; Gerber et al., 1998a; Gerber et al., 2002; Gerber et al., 1998b), and here we describe a role…”
BackgroundSelf-citationHypoxia or in situ normoxia: The stem cell paradigm
Ivanovic, Z. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21690 · Cited by 406
“…regulator in angiogenesis and brain development, that is, as a non-hematopoietic regulator (Arcasoy, 2008) (c) VEGF is acting as a key regulator of physiological angiogenesis during embryogenesis, endochondrial bone formation, female reproductive functions (reviewed in Ferrara et al., 2003). . .”
BackgroundTherapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
The role of integrins in inflammation and angiogenesis
Mezu-Ndubuisi, O. J., & Maheshwari, A. (2021) · Pediatric Research · doi:10.1038/s41390-020-01177-9 · Cited by 384
Johansen, J. S. (2006) · PubMed · Cited by 444
Angiogenesis in the atherosclerotic plaque
Camaré, C., Pucelle, M., Nègre-Salvayre, A., & Salvayre, R. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.007 · Cited by 401
“The VEGFA gene gives rise to multiple VEGF-A isoforms, designated by VEGFxxx (xxx indicating the number of amino acid residues, e.g. VEGF121, VEGF145, VEGF165, VEGF189, VEGF206), which are generated by alternative exon splicing [69,70] and by various post-transcriptional mechanisms (e.g. alternative initiation codons,…”
BackgroundInfluentialDll4 and Notch signalling couples sprouting angiogenesis and artery formation
Pitulescu, M. E., Schmidt, I., Giaimo, B. D., Antoine, T., Berkenfeld, F., Ferrante, F., Park, H., Ehling, M., Biljes, D., Rocha, S. F., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3555 · Cited by 393
Self-citationMartin, D., Galisteo, R., & Gutkind, J. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.c800207200 · Cited by 388
Cellular and Molecular Dynamics in the Foreign Body Reaction
Luttikhuizen, D. T., Harmsen, M. C., & Luyn, M. J. A. V. (2006) · Tissue Engineering · doi:10.1089/ten.2006.12.1955 · Cited by 396
“…express the chemo-kines CXCL-1, -2, and -8, which, after binding to the C-X-C chemokine receptor (CXCR)-2, 26 promotes VEGF expression by PMNs. 27 30 After this first angiogenic pulse, this signal is maintained by recruited macrophages and fibroblasts that move beyond the range of oxygen diffusion.”
Corneal Neovascularization: An Anti-VEGF Therapy Review
Chang, J.-H., Garg, N. K., Lunde, E., Han, K.-Y., Jain, S., & Azar, D. T. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.007 · Cited by 381
Ji, L., Brkić, J., Liu, M., Fu, G., Peng, C., & Wang, Y.-L. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.12.008 · Cited by 387
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy
Gately, S., & Li, W. W. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.03.040 · Cited by 398
Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects
Perez, J. R., Kouroupis, D., Li, D. J., Best, T. M., Kaplan, L., & Correa, D. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00105 · Cited by 390
“…that blockade of VEGF in mice and primates by monoclonal antibodies suppresses nearly all blood vessel invasion in the area, consequently impairing trabecular bone formation (Ryan et al., 1999), while stopping anti-VEGF treatment results in the return of normal bone growth (Ferrara et al., 2003).”
BackgroundZhou, H., Liang, B., Jiang, H., Deng, Z., & Yu, K. (2021) · Journal of Magnesium and Alloys · doi:10.1016/j.jma.2021.03.004 · Cited by 377
One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
Do, D. V., Nguyen, Q. D., Boyer, D., Schmidt-Erfurth, U., Brown, D. M., Vitti, R., Berliner, A. J., Gao, B., Zeitz, O., Ruckert, R., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.010 · Cited by 385
Angiogenesis drives psoriasis pathogenesis
Heidenreich, R., Röcken, M., & Ghoreschi, K. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00669.x · Cited by 383
“Interestingly, therapy with sunitinib (SU-011248), an inhibitor of VEGFR-2, plateletderived growth factor receptor (PDGFR) and fibroblast growth factor receptor (Kerbel & Folkman 2002; Faivre et al. 2006), may improve psoriasis at least in single patients (Keshtgarpour & Dudek 2007).”
BackgroundInfluentialMcDougall, S. R., Anderson, A. R. A., & Chaplain, M. A. J. (2006) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.12.022 · Cited by 383
“More recent individual summaries of selected components of angiogenesis can be found in the papers of Carmeliet (2003), Cleaver and Melton (2003), Ferrara et al. (2003), Jain (2003), Pugh and Ratcliffe (2003), Rafii and Lyden, (2003), Ylä-Herttuala and Alitalo (2003).”
BackgroundVascular endothelial growth factor family of ligands and receptors: Review
Otrock, Z. K., Makarem, J. A., & Shamseddine, A. I. (2007) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2006.12.003 · Cited by 376
NFAT proteins: emerging roles in cancer progression
Mancini, M., & Toker, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2735 · Cited by 371
“As with most mitogens, VEGFA stimulates receptor-mediated activation of PLCγ, leading to an increase in intracellular calcium, calcineurin activation and NFAT nuclear translocatio”
BackgroundHAO, X., SILVA, E., MANSSONBROBERG, A., GRINNEMO, K., SIDDIQUI, A., DELLGREN, G., WARDELL, E., BRODIN, L., MOONEY, D., & SYLVEN, C. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.03.028 · Cited by 377
“VEGF is an endothelial specific growth factor that mainly induces angiogenesis [13,14], and our results are consistent with the accepted mechanism of VEGF-A165 action.”
ResultCancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 372
Mustroph, A., Lee, S. C., Oosumi, T., Zanetti, M. E., Yang, H., Ma, K., Yaghoubi-Masihi, A., Fukao, T., & Bailey-Serres, J. (2010) · Plant Physiology · doi:10.1104/pp.109.151845 · Cited by 382
“…tissues, and stimulate red blood cell formation, as evidenced by enrichment in DEGs encoding proteins associated with these processes (Supplemental Tables S6 and S7a; i.e. vascular endothelial growth factor [OMCL4003; Ferrara et al., 2003] and adrenomedullin [OMCL16253; Guidolin et al., 2008]).”
BackgroundSanchez, T., Estrada-Hernandez, T., Paik, J.-H., Wu, M.-T., Venkataraman, K., Brinkmann, V., Claffey, K., & Hla, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306896200 · Cited by 374
Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis
Langley, R. R., & Fidler, I. J. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0027 · Cited by 373
“VEGF belongs to a gene family that includes placental growth factor, VEGFB, VEGFC, and VEGFD (98).”
BackgroundCombination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 370
“VEGF and VEGFR play an essential role in vascular development as exemplified by the embryonic lethality of targeted disruptions in the genes coding for VEGF and VEGFR-2 (21).”
BackgroundInfluentialRole of angiogenesis in bone repair
Saran, U., Gemini Piperni, S., & Chatterjee, S. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.006 · Cited by 362
Angiogenesis and hepatocellular carcinoma
Semela, D., & Dufour, J.-F. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.006 · Cited by 372
“[26] Ferrara N, Gerber HP, LeCouter J.”
Background
Metadata
- Authors
- Ferrara, N., Gerber, H.-P., & LeCouter, J.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature Medicine
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 669-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2000292756
- Cited by
- 9,591
- References
- 144
- Citations by year
- 2026: 154 · 2025: 270 · 2024: 292 · 2023: 317 · 2022: 336 · 2021: 386 · 2020: 379 · 2019: 403 · 2018: 384 · 2017: 466 · 2016: 460 · 2015: 485 · 2014: 551 · 2013: 527 · 2012: 580
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vascular endothelial growth factor, VEGF receptors, VEGFR1, VEGFR2, receptor tyrosine kinase signaling, angiogenesis, pathological angiogenesis, tumor angiogenesis, intraocular neovascularization, VEGF inhibitors, age-related macular degeneration, vascular leakage, embryonic development
- MeSH terms
- Animals, Clinical Trials as Topic, Endothelium, Vascular, Growth Substances, Humans, Lymphokines, Neovascularization, Pathologic, Oxygen, Signal Transduction, Endothelial Growth Factors, Neovascularization, Physiologic, Protein Isoforms, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.